Pacira BioSciences Inc (PCRX)
16.51
+0.62
(+3.90%)
USD |
NASDAQ |
Oct 04, 16:00
16.51
0.00 (0.00%)
After-Hours: 20:00
Pacira BioSciences Shareholders Equity (Annual): 870.13M for Dec. 31, 2023
Shareholders Equity (Annual) Chart
Historical Shareholders Equity (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 870.13M |
| December 31, 2022 | 775.01M |
| December 31, 2021 | 730.41M |
| December 31, 2020 | 619.69M |
| December 31, 2019 | 354.94M |
| December 31, 2018 | 321.23M |
| December 31, 2017 | 279.48M |
| December 31, 2016 | 218.98M |
| Date | Value |
|---|---|
| December 31, 2015 | 218.39M |
| December 31, 2014 | 171.14M |
| December 31, 2013 | 41.25M |
| December 31, 2012 | 65.86M |
| December 31, 2011 | 48.27M |
| December 31, 2010 | -48.38M |
| December 31, 2009 | -22.95M |
| December 31, 2008 | 7.49M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Annual) Range, Past 5 Years
354.94M
Minimum
2019
870.13M
Maximum
2023
670.04M
Average
730.41M
Median
2021
Shareholders Equity (Annual) Benchmarks
| Amgen Inc | 6.232B |
| Biogen Inc | 14.80B |
| Gilead Sciences Inc | 22.83B |
| Merck & Co Inc | 37.58B |
| Revance Therapeutics Inc | -151.60M |